Short-term results of switchback from aflibercept to ranibizumab in neovascular age-related macular degeneration in clinical practice

Purpose This work was undertaken to analyze the efficacy of switchback from aflibercept to ranibizumab in patients with neovascular age-related macular degeneration (nAMD) who had previously switched from ranibizumab to aflibercept. Methods This retrospective double-center study included 45 patients...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Graefe's archive for clinical and experimental ophthalmology Ročník 254; číslo 4; s. 639 - 644
Hlavní autori:	Despreaux, Raphaelle, Cohen, Salomon Y., Semoun, Oudy, Zambrowski, Olivia, Jung, Camille, Oubraham, Hassiba, Souied, Eric H.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Berlin/Heidelberg Springer Berlin Heidelberg 01.04.2016 Springer Nature B.V
Predmet:	Aged Aged, 80 and over Angiogenesis Inhibitors - therapeutic use Drug Substitution Female Fluorescein Angiography Follow-Up Studies Humans Intravitreal Injections Macular degeneration Male Medicine Medicine & Public Health Middle Aged Ophthalmology Ranibizumab - therapeutic use Receptors, Vascular Endothelial Growth Factor - therapeutic use Recombinant Fusion Proteins - therapeutic use Retinal Disorders Retrospective Studies Tomography, Optical Coherence Treatment Outcome Vascular Endothelial Growth Factor A - antagonists & inhibitors Visual Acuity - drug effects Wet Macular Degeneration - diagnosis Wet Macular Degeneration - drug therapy Wet Macular Degeneration - physiopathology Choroidal neovascularization Switch Age-related macular degeneration Ranibizumab Anti-VEGF Aflibercept Switchback
ISSN:	0721-832X, 1435-702X
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!